Business
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026, at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reporte
About this update from Zevra Therapeutics, Inc.
[{"type":"image","alt":"Zevra Therapeutics","displaySize":"","headline":null,"caption":"Zevra Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/47aa28c5ce5943ac0fb423dcc40d01c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c42x5R3WvKAr04ITFEGgaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/47aa28c5ce5943ac0fb423dcc40d01c5","width":300,"height":80}},"lazy":false},{"type":"text","content":"Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025","length":65,"tagName":"p"},{"type":"text","content":"Completed $50.0 million sale of SDX portfolio to Commave Therapeutics ","length":69,"tagName":"p"},{"type":"text","content":"Operational execution fueled strong cash position of $236.8 million","length":67,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast TODAY, May 6, 2026, at 4:30 p.m. ET","length":84,"tagName":"p"},{"type":"text","content":"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026.","length":283,"tagName":"p"},{"type":"text","content":"“We made meaningful progress across the business in the first quarter, led by continued performance for MIPLYFFA, underscoring its role in addressing the needs of patients with Niemann-Pick disease type C,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “We also completed the $50.0 million divestiture of the SDX portfolio, and we repaid our term loan debt, sharpening our strategic focus and strengthening our financial position as we execute on our 2026 priorities.”","length":497,"tagName":"p"},{"type":"text","content":"MIPLYFFA® (arimoclomol) Highlights ","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"U.S.: Received nine MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q1 2026, bringing the total to 170 since product launch. Market access remains stable at 69% of covered lives. ","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"EU: A Marketing Authorisation Application for the e...